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Inability to switch from ARID1A-BAF to ARID1BBAF impairs exit from pluripotency and
commitment towards neural crest formation in
ARID1B-related neurodevelopmental disorders
Luca Pagliaroli 1,9, Patrizia Porazzi2,9, Alyxandra T. Curtis1, Chiara Scopa1, Harald M. M. Mikkers3,
Christian Freund4, Lucia Daxinger 5, Sandra Deliard6, Sarah A. Welsh6, Sarah Ofﬂey 6, Connor A. Ott
Bruno Calabretta2, Samantha A. Brugmann7, Gijs W. E. Santen8,10 & Marco Trizzino 1,10 ✉

1,

Subunit switches in the BAF chromatin remodeler are essential during development. ARID1B
and its paralog ARID1A encode for mutually exclusive BAF subunits. De novo ARID1B haploinsufﬁcient mutations cause neurodevelopmental disorders, including Cofﬁn-Siris syndrome, which is characterized by neurological and craniofacial features. Here, we leveraged
ARID1B+/− Cofﬁn-Siris patient-derived iPSCs and modeled cranial neural crest cell (CNCC)
formation. We discovered that ARID1B is active only during the ﬁrst stage of this process,
coinciding with neuroectoderm speciﬁcation, where it is part of a lineage-speciﬁc BAF conﬁguration (ARID1B-BAF). ARID1B-BAF regulates exit from pluripotency and lineage commitment by attenuating thousands of enhancers and genes of the NANOG and SOX2
networks. In iPSCs, these enhancers are maintained active by ARID1A-containing BAF. At the
onset of differentiation, cells transition from ARID1A- to ARID1B-BAF, eliciting attenuation of
the NANOG/SOX2 networks and triggering pluripotency exit. Cofﬁn-Siris patient cells fail to
perform the ARID1A/ARID1B switch, and maintain ARID1A-BAF at the pluripotency enhancers throughout all stages of CNCC formation. This leads to persistent NANOG/SOX2
activity which impairs CNCC formation. Despite showing the typical neural crest signature
(TFAP2A/SOX9-positive), ARID1B-haploinsufﬁcient CNCCs are also aberrantly NANOGpositive. These ﬁndings suggest a connection between ARID1B mutations, neuroectoderm
speciﬁcation and a pathogenic mechanism for Cofﬁn-Siris syndrome.
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ell fate commitment is a complex process that requires
timely regulation of developmental genes. This phenomenon is mediated by the concerted activity of transcription
factors and chromatin regulators that modulate the interaction
between cis-regulatory elements (enhancers, promoters) and RNA
Polymerase II to promote gene expression. In this framework, a
key role is played by the Brg1/Brm associated factor (BAF)
chromatin-remodeling complex. BAF leverages ATP to modulate
nucleosome positioning and chromatin accessibility genomewide1. Different conﬁgurations of BAF, with context-speciﬁc
functions, have been described, and switches between subunits
have been reported to be linked to speciﬁc developmental
stages2,3. All known canonical BAF conﬁgurations require the
presence of a subunit containing an AT-rich DNA binding
domain (ARID). Namely, in the BAF complex, this function is
carried out by two mutually exclusive subunits: ARID1A and
ARID1B4–6. Previous studies in mouse embryonic stem cells
(mESCs) have identiﬁed an ESC-speciﬁc conﬁguration of BAF
which regulates pluripotency and self-renewal of embryonic stem
cells (esBAF)4–6. Importantly, the esBAF predominantly incorporates ARID1A and very rarely ARID1B (relative ARID1B
abundance in the esBAF was quantiﬁed as ~0 by Ho et al.6). One
of these studies also identiﬁed a non-canonical version of BAF
(gBAF), which did not contain an ARID subunit and was
involved in pluripotency maintenance of mESCs4.
De novo haploinsufﬁcient mutations in the ARID1B gene cause a
spectrum of neurodevelopmental disorders, ranging from CofﬁnSiris syndrome to non-syndromic intellectual disability (ID)7–12.
Cofﬁn-Siris syndrome is associated with ID, speciﬁc craniofacial
features, growth impairment, feeding difﬁculties, and congenital
anomalies such as heart and kidney defects13. Although other BAF
components may also be mutated in this syndrome, ~75% of the
mutations are in ARID1B11,14,15. In addition to Cofﬁn-Siris,
genome-wide sequencing in unselected cohorts of patients with ID
shows that ARID1B is always in the top-5 of causative genes,
explaining ~1% of all ID cases9,16. Whereas several studies utilizing
murine models recapitulate the neurological phenotypes typical of
the ARID1B-associated syndromes17–20, the molecular function of
ARID1B in cell fate commitment during human development is still
poorly understood.
Several hallmark features of ARID1B-haploinsufﬁcient individuals, including severe craniofacial, cardiac and digestive system
abnormalities, suggest impaired neural crest cell migration as a
pathological etiology12. Further, ARID1B is one of the most
commonly mutated genes in neuroblastoma, a pediatric tumor of
neural crest origin21. Thus, neural crest formation, migration, and
differentiation represent suitable models to study the consequences of ARID1B mutations. To speciﬁcally address the
molecular consequences of ARID1B-haploinsufﬁcient mutations
in neural crest formation and development, we reprogrammed
skin ﬁbroblasts of two unrelated ARID1B+/− Cofﬁn-Siris patients
into induced Pluripotent Stem Cells (iPSCs) and used these
patient-derived iPSCs to speciﬁcally model formation of cranial
neural crest cell (CNCC), a multipotent cell population that forms
through a neuroectodermal sphere intermediate that eventually
gives rise to migratory CNCCs.
Herein, we report the discovery of a lineage-speciﬁc BAF
conﬁguration, containing ARID1B, SMARCA4, and additional
subunits (ARID1B-BAF). In line with ﬁndings indicating that the
esBAF and the gBAF do not contain ARID1B4–6, we demonstrate
that ARID1B mutations do not affect self-renewal and pluripotency of human iPSCs, as pluripotency is conveyed via binding
of an ARID1A-containing BAF to pluripotency-associated
enhancers of the SOX2 and NANOG networks. On the other
hand, we show that ARID1B-BAF is required for lineage speciﬁcation and exit from pluripotency. In fact, ARID1B-BAF is only
2

transiently active during the early stages of iPSC-to-CNCC differentiation, and speciﬁcally during the formation of the neuroectodermal spheres, where it replaces ARID1A-BAF at the
SOX2/NANOG enhancers and elicits their repression.
Importantly, we demonstrate that ARID1B+/− cells from
Cofﬁn-Siris patients are unable to switch from ARID1A-BAF to
ARID1B-BAF at the onset of neuroectoderm formation, and
instead maintain ARID1A-BAF at pluripotency enhancers
throughout the entire differentiation process. Failure to replace
ARID1A with ARID1B leads to defective exit from pluripotency
and impaired cranial neural crest formation. These ﬁndings
provide evidence for a direct connection between ARID1B
mutations and a pathogenic mechanism for ARID1B-associated
neurodevelopmental syndromes.
Results
Cofﬁn-Siris patient-derived iPSCs are pluripotent and proliferate normally. To investigate the function of ARID1B in
craniofacial development, we obtained skin ﬁbroblasts from two
unrelated ARID1B+/− Cofﬁn-Siris Syndrome patients (hereafter,
Patient 19 and Patient 26; Fig. 1a, b), one male and one female,
both carrying previously identiﬁed de novo ARID1B mutations.
In detail, Patient 19 presented a non-sense mutation (c.3223
C > T;p.Arg1075*; Fig. 1b), whereas Patient 26 had a frameshift
mutation (c.2598del;Tyr867Thrfs*47; Fig. 1b)10,14. In both cases,
a premature STOP codon was generated (Fig. 1b).
The ﬁbroblasts were reprogrammed into iPSCs by the LUMC
hiPSC Hotel (Leiden University). Patient-derived iPSCs exhibited
regular morphology (Fig. 1c) and expressed pluripotency genes,
as shown by both immunoﬂuorescence (Fig. 1d) and RT-qPCR
(Fig. 1e). Further, patient-derived iPSCs grew at the same rate as
an ARID1B+/+ control line (Control line-1; Fig. 1f).
Importantly, the aberrant STOP codon introduced by the
mutations was located either upstream (Patient 26) or inside
(Patient 19) the AT-rich interactive domain (ARID) (Fig. 1b),
which is required for ARID1B’s interaction with chromatin22.
Moreover, in both patients, the new STOP codon was localized
upstream of the nuclear localization signal (NLS, Fig. 1b),
suggesting that the gene product arising from the mutated allele
would not be able to reach the nucleus or access the chromatin,
even in the unlikely case that the transcript escaped non-sense
mediated mRNA decay23. To test this, we performed cellular
fractionation in patient and control iPSCs and conducted an
ARID1B western blot on the chromatin fraction with an antibody
raised against a peptide in the N-terminus of ARID1B, upstream of
the mutated regions (sc-32762). Consistent with our hypothesis, the
immunoblot on the chromatin fraction revealed a signiﬁcantly
reduced amount of ARID1B protein in both patient samples relative
to the control ARID1B+/+ iPSC line (Control line-1; Supplementary
Fig. 1a). ARID1B was reduced by ~60% and 80% in Patients 19 and
26, respectively. ARID1B was not detected in the cytoplasmic or
nuclear fraction of any cell lines (Supplementary Fig S1a). Thus,
ARID1B-haploinsufﬁcient iPSCs remained pluripotent, did not
exhibit any growth defects, but did display signiﬁcantly less
chromatin-bound ARID1B than control iPSCs.
CNCC formation is impaired in Cofﬁn-Siris patient-derived
iPSCs. Utilizing published methods for iPSC-to-CNCC
differentiation24 we generated CNCCs from control iPSCs, in
14 days (Fig. 2a, b). A time-course western blot conducted during
the differentiation of Control line-1 revealed that ARID1B protein
was robustly expressed during the ﬁrst week of differentiation,
peaking between days 5 and 7, with some expected variability
between biological replicates (Fig. 2c; see Fig. 7 for a second
replicate). After day 7; however, ARID1B protein was markedly
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Fig. 1 iPSCs derived from Cofﬁn-Siris patients are pluripotent and proliferate normally. a Study system: iPSCs were derived from skin ﬁbroblasts of two
unrelated Cofﬁn-Siris patients. The iPSCs were used in this study to generate Cranial Neural Crest Cells (CNCCs) and perform genomic experiments to
investigate the effect of ARID1B mutations. Panel created by LP. b Graphical illustration of the ARID1B-haploinsufﬁcient mutations affecting the two studied
patients. The numbers in the gene model refer to ARID1B’s isoform NM_020732.3. c iPSC colony derived from Patient 19. d, e Immunoﬂuorescence and rtqPCR quantifying the expression of the key pluripotency markers in iPSCs derived from Control and Patient lines. P values are from two-sided Student’s t
test. N = 3 biologically independent samples. Error bars display standard errors. f Growth curve comparing an ARID1B-wt iPSC Line (CTRL-1) with the two
patient lines. P values from two-sided Student’s t test are >0.05 (not signiﬁcant) in all comparisons. N = 3 biologically independent experiments. Error bars
display standard errors.

downregulated (Fig. 2c). The window of robust ARID1B
expression (day 0 to day 7) coincided with the differentiation of
the iPSCs into neuroectodermal spheres, suggesting that this BAF
subunit may have a role in neuroectoderm speciﬁcation.

Next, we induced CNCC differentiation in two Cofﬁn-Siris patient
lines and compared them with Control iPSC-derived CNCCs using
ﬂow cytometry to measure multiple pluripotency (SSEA4, TRA-1-60R) and CNCC (CD10, CD99) surface markers. Cells were sampled at
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Fig. 2 CNCC differentiation is impaired in the patient cells. a, b CNCC differentiation was optimized using an ARID1B-wt control line. After 14 days, the
cells exhibited the classic CNCC morphology and expressed the CNCC markers. P values are from two-sided Student’s t test. N = 3 biologically
independent samples. Error bars display standard errors. c Time-course immunoblot conducted using Control Line-1 during CNCC differentiation shows
that ARID1B is active in the ﬁrst 7 days of the differentiation, with a peak of activity between day 5 and day 7. The ARID1B protein level strongly decreases
after day 7. The experiment was repeated twice (the second replicate is shown in Fig. 7). Marker bars display kDa. d, e Flow cytometry quantifying the
expression of surface markers for pluripotency and CNCC differentiation in Control Line-1 and in the two patient lines. A large cell population is still
pluripotent in both patients after 14 days (d). The patient lines also show reduced expression of CNCC surface markers after 14 days of differentiation
relative to an ARID1B-wt control line at the same time point (e).

day-zero (iPSCs), day 5 (neuroectoderm), and day 14 (CNCC).
Notably, CNCC formation was impaired in both patient-derived
lines, as evident by a sizable cell population that was double-positive
for pluripotency surface markers even after 14 days of differentiation
(Fig. 2d; Supplementary Fig. 2). This double-positive population
comprised 4.5% and 19.5% of the cells in the two patient lines,
respectively (Fig. 2d). In line with this, a large fraction of patient cells
showed signiﬁcantly lower expression of CNCC surface markers even
after 14 days of differentiation relative to the control line (Fig. 2e).
To further characterize patient-derived CNCCs, we performed
immunoﬂuorescence for pluripotency (OCT4, NANOG) and
neural crest (SOX9) markers, in control and patient lines at day
14. Interestingly, CNCCs derived from patient iPSCs displayed a
gene expression signature distinct from that of control CNCCs
4

(Fig. 3). In fact, nearly all patient-derived CNCCs were positive
for SOX9, NANOG (Patients 19 and 26), and OCT4 (Patient 26
only; Fig. 3). This was in sharp contrast to the control line, in
which SOX9-positive cells were almost all OCT4- and NANOGnegative (Fig. 3; See Supplementary Fig. 3 for quantiﬁcations and
p values). Together, these data suggested that while ARID1B is
dispensable for pluripotency, haploinsufﬁciency of this gene
severely impaired CNCC formation, resulting in CNCCs expressing key pluripotency genes.
Chromatin accessibility is dysregulated in differentiating
Cofﬁn-Siris patient-derived lines. We used next-generation
sequencing to investigate why ARID1B-haploinsufﬁcient Cofﬁn-
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Fig. 3 Aberrant NANOG and OCT4 activity in the patient-derived CNCC. Immunoﬂuorescence for SOX9, NANOG, and OCT4 was performed on day 14
of iPSC-to-CNCC differentiation in Control Line-1, Patient 19, and Patient 26 cells.

Siris iPSCs did not successfully differentiate into CNCCs. Given
that ARID1B protein levels in control cells reach a peak between
days 5 and 7, samples were taken on day 5 to perform genomic
analyses. Experiments were conducted with two biological replicates per condition (two control lines, two patient lines). For each
condition, a male and a female were included to avoid sex-speciﬁc
confounding effects. Technical replicates were also used for each
biological replicate. To avoid batch effects, all the biological
replicates and conditions were processed together.
Since ARID1B is a component of the BAF chromatin-remodeling
complex, we proﬁled chromatin accessibility with ATAC-seq.
Overall, at day 5, 29,758 ATAC-seq peaks were identiﬁed across all
replicates and conditions (patients and controls; false discovery rate
(FDR) < 0.05; Fig. 4a). Conversely, 5540 peaks were speciﬁc to the
patient iPSCs (i.e., replicated in all patient’s iPSC replicates and not
detected in any of the controls; hereafter patient-speciﬁc ATAC-seq
regions; Fig. 4a, b; Supplementary Data 1). Finally, only 578 peaks
were speciﬁc to the controls (hereafter control-speciﬁc ATAC-seq
regions; Fig. 4a, c; Supplementary Data 1). We, therefore, focused on
the 5540 patient-speciﬁc ATAC-seq regions because they represented
91% (5540/6118) of all regions with differential chromatin
accessibility between patient and control lines.
On day 0, ATAC-seq performed in iPSCs revealed that the 5540
regions were highly accessible, with no signiﬁcant differences between
patient and control lines (Supplementary Fig. 4a). By day 5, this
dramatically shifted and 5511 of the 5540 regions (99.4%) were called
peaks exclusive to the patient lines. These data suggested that these
were regions highly accessible in iPSCs and repressed by day 5 of
iPSC-to-CNCC differentiation. Such repression is impaired by
ARID1B haploinsufﬁciency, indicating that chromatin accessibility
in the 5540 genomic sites may be directly regulated by an ARID1Bcontaining BAF during exit from pluripotency and neuroectoderm
speciﬁcation. Thus, we investigated ARID1B’s binding at these
regions both in day 0 (iPSCs) and in day 5 cells. On day 0, these
regions were not bound by ARID1B (Supplementary Fig. 4b). This
was expected, given that that ARID1B is not found in the gBAF,

whereas ARID1A is the predominant ARID1 in the esBAF4–6, and
likely explains why differences in chromatin accessibility at these
regions between patient and control lines at day 0 was not observed.
On the other hand, at the day 5, the 5540 regions were bound
by ARID1B in both control lines (6486 ARID1B peaks detected
on average in the two CTRL lines), while the binding was almost
entirely lost in both patient lines (Fig. 4d; only 750 peaks detected
on average in the ARID1B-deﬁcient patient lines). This loss of
binding correlated with a lack of chromatin repression in both
patient lines. Together, these ﬁndings indicated that gain of
ARID1B binding at these 5540 genomic sites in the early stages of
iPSC-to-CNCC differentiation may be required for repression of
the pluripotency program.
The ARID1B-BAF attenuates thousands of enhancers at the
onset of CNCC differentiation. To determine the nature of the
5540 genomic regions, we associated a gene to each region based
on the distance from the nearest transcription start site (TSS).
Overall, 87.5% of the ARID1B ChIP-seq peaks were located
>10 Kbs from the nearest TSS and may represent putative
enhancers, whereas the remaining 12.5% are likely promoters.
ChIP-seq time-course for H3K27ac in control cells revealed that
many of these regulatory regions were enriched for H3K27ac in
iPSCs, progressively lost this enrichment during differentiation,
and by day 5 had very reduced H3K27ac signal (Fig. 4e). The
gradual decrease in H3K27ac mirrored the steady increase in
ARID1B expression detected during the early stages of iPSC-toCNCC differentiation, and speciﬁcally during the formation of
the neuroectodermal spheres (Fig. 2c). Consistent with this, the
differentiating cells from both patients had signiﬁcantly higher
levels of H3K27ac in these regions, relative to the two control
lines at day 5 (Wilcoxon’s Rank-Sum Test p < 2.2 × 10−16 in all
the patient vs control pairwise comparisons; Fig. 4f, g).
We further investigated the fate of these regions over the
course of iPSC-to-CNCC differentiation. We performed ChIP-seq
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Fig. 4 Chromatin remodeling at pluripotency enhancers is dysregulated in the patient cells. a At CNCC day 5, 29,578 ATAC-seq peaks are shared
between patient and control lines. In all, 5540 peaks are speciﬁc to the patients. 578 peaks are speciﬁc to the controls. b UCSC Genome Browser example
of a patient-speciﬁc ATAC-seq peak. c UCSC Genome Browser example of a CONTROL-SPECIFIC ATAC-seq peak. d ARID1B ChIP-seq heatmaps (Four
lines; CNCC Day 5) centered on the patient-speciﬁc ATAC-seq peaks; the UCSC screenshot shows ARID1B binding at a patient-speciﬁc ATAC-seq peak
(chr10:129,590,000–129,595,000) in the control and patient lines at iPSC stage and at CNCC Day 5. e Spike-in normalized heatmaps of H3K27ac ChIPseq time-course at the 5540 patient-speciﬁc ATAC-seq peaks (Control Line-1). f Spike-in normalized H3K27ac ChIP-seq average proﬁles centered on the
patient-speciﬁc ATAC-seq regions (CNCC Day 5). Statistical signiﬁcance was assessed with Wilcoxon’s Rank-Sum test (p < 2.2 × 10−16 in all the patient vs
control comparisons). g Spike-in normalized heatmaps of H3K27ac ChIP-seq signal at Days 5, 7, and 9 at the 5540 patient-speciﬁc ATAC-seq peaks
(Control Line-1, Patient 19, Patient 26). h Motif analysis at the patient-speciﬁc ATAC-seq regions revealed enrichment for the binding motif of multiple
pluripotency factors. P values are calculated by Meme-ChIP as E values. The E value is the motif P value (computed by Fisher’s Exact Test) times the
number of candidate motifs tested.
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for H3K27ac in CTRL line-1, P19, and P26 on days 5, 7, and 9
(peak numbers ranged from 96,600 on day 5 to 153,134 on day 9).
We found that the patient-speciﬁc cis-regulatory elements were
inactive in the control line at day 7, but still largely active in the
patient lines at the same time point (Fig. 4g). Interestingly, on day
9 of differentiation, these regions were inactivated (i.e., no
H3K27ac signal) in Patient 19 line, while remaining active (i.e.,
persistent H3K27ac signal) in the Patient 26 line (Fig. 4g).
Based on the high H3K27ac signal that the 5540 patientspeciﬁc regions display at the iPSC stage (Fig. 4e), we surmised
that these sites could represent cis-regulatory elements important
for pluripotency. In line with this hypothesis, DNA-motif analysis
on the 5540 regions revealed that they were enriched for the
binding sites of multiple pluripotency factors, including SOX2
and NANOG (Fig. 4h; Supplementary Data 2).
To ensure that the molecular phenotypes observed were
directly caused by the ARID1B mutations, and not by cooccurring mutations in other genes coincidentally shared by both
(unrelated) patients we employed shRNAs to knock-down
ARID1B in the Control Line-1. We were able to obtain a partial
knock-down of ARID1B at the iPSC stage (shRNA-1; Supplementary Fig. 4c), which represented a suitable model for ARID1B
haploinsufﬁciency. ARID1B-KD iPSCs were put through the
CNCC differentiation protocol, collected at day 5, and proﬁled via
ATAC-seq and ChIP-seq for H3K27ac. Notably, both sequencing
experiments perfectly recapitulated our ﬁndings in the patientderived lines. Upon ARID1B-KD, we detected signiﬁcantly
increased chromatin accessibility and H3K27ac signal in the
5540 patients-speciﬁc regions relative to the same iPSC line
transduced with a control shRNA (Wilcoxon’s rank-sum test
p < 2.2 × 10−16; Supplementary Fig. 4d, e).
Together, these data indicate that ARID1B-BAF modulates the
chromatin accessibility of a speciﬁc set of ~4900 pluripotency
enhancers and ~600 promoters that are highly active in iPSCs,
moderately active at the onset of neuroectoderm formation, and
inactive by day 7 and for the remaining course of CNCC
formation (Fig. 4e). These data suggested that impaired
attenuation of these cis-regulatory elements in the ARID1Bhaploinsufﬁcient cells, subsequently hampers the entire differentiation process towards a CNCC fate.
Pluripotency and exit from pluripotency genes are dysregulated in differentiating patient lines. Impaired attenuation of
~4900 pluripotency-relevant enhancers and ~600 promoters
could have a profound effect on gene expression levels. Indeed,
RNA-seq conducted at day 5 identiﬁed 2356 differentially
expressed genes, 1685 of which were downregulated, and 671
upregulated (FDR < 5%; Fig. 5a). As expected, ARID1B was one of
the top downregulated genes in patient CNCCs (Fig. 5a). In stark
contrast, only 54 genes were identiﬁed as differentially expressed
when we performed RNA-seq at the iPSC stage (FDR < 5%). This
suggested that ARID1B is important for lineage commitment,
again mirroring the progressive increase in the ARID1B protein
level observed during the early stages of differentiation (Fig. 2c).
The small number of differentially expressed genes identiﬁed at
the iPSC stage was again consistent with the ﬁnding that esBAF
and gBAF do not include ARID1B4–6.
Notably, 598/2356 (25.4%) of the genes differentially expressed at
day 5 also represented the nearest gene to one of the 5540
pluripotency enhancers and promoters aberrantly active in the
Cofﬁn-Siris patient cells at the same time point (Supplementary
Data 3). These results suggested that over a quarter of differentially
expressed genes were under the direct control of ARID1B-BAF
throughout modulation of chromatin accessibility at associated
enhancers and promoters. As expected, when we compared these
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598 genes against the entire set of 2356 differentially expressed
genes, we found that the 598 genes exhibited enrichment for genes
upregulated in patient cells (Fisher’s Exact Test p < 0.0001).
Ingenuity-Pathway Analysis on the 598 genes identiﬁed ﬁve of the
top canonical pathways as associated with either pluripotency or exit
from pluripotency, as well as Wnt-β catenin signaling pathway25,26
(Fig. 5b; Supplementary Data 4).
In accordance with the ATAC-seq data, SOX2 was detected
among the top upstream regulators (Fig. 5c), and three of the
most important pluripotency factors, NANOG, SOX2, and
POU5F1 (OCT4) were highly expressed in the patient lines at
day 5 (Fig. 5d).
Both the [Role of NANOG in Mammalian Embryonic Stem
Cell Pluripotency] and the [PPARα/RXRα Activation] pathways
were enriched in the 598 genes (Fig. 5b). Namely, the genes
belonging to the former pathway were all upregulated, while those
belonging to the latter were downregulated (Fig. 5d). These two
pathways caught our attention because they are thought to
antagonize each other. More speciﬁcally, NANOG blocks the
differentiation of pluripotent cells and establishes the pluripotent
state during somatic cell reprogramming. Conversely, the
PPARα/RXRα pathway is activated at the onset of differentiation
to promote exit from pluripotency27. The activation of PPARα/
RXRα contributes to the repression of the NANOG network to
allow efﬁcient exit from the undifferentiated stage27–29. Consistent with this, PPARα-inhibitors have been employed to
improve iPSC reprogramming27.
These gene expression data were in line with the immunoﬂuorescence ﬁndings and with the perpetual NANOG and OCT4
expression in patient-derived CNCCs at day 14 of differentiation
(Fig. 3).
Finally, we looked for potential overlap between our set of 2356
differentially expressed genes at day 5 of iPSC differentiation
toward CNCC and a set of genes identiﬁed as differentially
expressed in a recent RNA-seq study which compared cerebellar
tissue of ARID1B+/− and ARID1B-wt mice30. Notably, 1297 of
the 2356 genes (55%) found as differentially expressed in our
study were also found as differentially expressed in the KO-mouse
model data set. This overlap (55%) was signiﬁcantly higher than
expected by chance (Fisher’s exact test p < 2.2 × 10−16) and
suggested that the pathways regulated by ARID1B are important
for both craniofacial and brain development.
Taken together, our RNA-seq data suggested that differentiating
ARID1B+/− patient-derived lines exhibited a persistent upregulation
of multiple pluripotency factors and associated gene networks, along
with downregulation of genes responsible for exit from pluripotency.
Dysregulation of these gene networks subsequently impaired
neuroectoderm speciﬁcation and CNCC formation.
Aberrant SOX2 and NANOG activity in the ARID1B-haploinsufﬁcient patient cells. Our experiments indicate that the
ARID1B-haploinsufﬁcient cells fail to attenuate thousands of
pluripotency enhancers and promoters enriched for SOX2 and
NANOG-binding sites (Fig. 4a–h). Further, on day 5 of iPSC-toCNCC differentiation, the expression of SOX2 and NANOG was
signiﬁcantly higher in the patient-derived cells than in the controls, and the gene regulatory networks associated with these
pluripotency factors were also upregulated (Fig. 5b–d). Moreover,
both patient-derived CNCCs (day 14) exhibited aberrant
expression of NANOG (Fig. 3).
Given these ﬁndings, we set out to investigate the binding
proﬁle of SOX2 and NANOG in patient and control lines by
ChIP-seq at CNCC day 5. Our spike-in normalized SOX2 ChIPseq revealed that 3284/5540 (59.7%) patient-speciﬁc ATAC-seq
peaks exhibit signiﬁcantly higher SOX2 binding in patients
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Fig. 5 Pluripotency and exit from pluripotency genes are dysregulated in differentiating patient CNCCs. a RNA-seq volcano plot shows the differentially
expressed genes between patient and control lines at CNCC Day 5. ARID1B is one of the top downregulated genes. b Top canonical pathways (IPA analysis)
enriched in the set of 598 differentially expressed genes that also represent the closest gene to a patient-speciﬁc ATAC-seq peak. c Top upstream
regulators (IPA analysis) enriched in the same set of 598 genes used for b. P values are calculated with Fisher’s Exact Test, adjusted using False Discovery
Rate (Benjamini–Hochberg). d RNA-seq heatmap displaying expression patterns at CNCC Day 5 for pluripotency genes, for genes of the NANOG network,
and for genes associated to exit from pluripotency (PPARα/RXRα activation pathway).

relative to control lines (Fig. 6a). In line with this, the chromatin
at these regions is accessible in the patient lines but not in the
control lines (Fig. 6b). SOX2 is a pioneer factor that can bind
condensed nucleosomes to open the chromatin and allow binding
of other factors31. As demonstrated by previous studies in mESCs,
SOX2 and other pluripotency pioneer factors (e.g., OCT4) require
the BAF complex to perform their pioneer activity6,31,32. Our
ﬁndings indicate that, in control conditions, the ARID1B-BAF
complex likely antagonizes the cooperation between other BAF
conﬁgurations and SOX2, counter-acting the pioneer activity of
the latter as soon as cell differentiation is induced. Further, we
identiﬁed an additional set of 497 SOX2 peaks speciﬁc to the
patient lines, which did not exhibit changes in chromatin
accessibility. Moreover, we also identiﬁed 1146 SOX2 peaks
exclusive of the control lines (Supplementary Data 5). Importantly, these control-speciﬁc SOX2 peaks were located in
proximity to genes associated with neural crest differentiation,
including TFAP2A, PAX6, PAX7, WNT4, ENO1, C8B, and
SERBP1 among others. These ﬁndings are consistent with two
recent studies which suggested that SOX2-chromatin interactions
are rewired upon differentiation cues33,34. Such rewiring appears
impaired in ARID1B-haploinsufﬁcient cells, which aberrantly
maintain SOX2 at pluripotency-associated enhancers, and at the
same time fail to reposition this transcription factor at the
developmental enhancers.
8

Next, we proﬁled NANOG at day 5 of differentiation. For this
transcription factor, the spike-in normalized ChIP-seq revealed
4538 peaks unique to the patients (Supplementary Data 6).
However, in this case, only 219 (4.8%) of the patient-speciﬁc
NANOG peaks overlapped a patient-speciﬁc ATAC-seq peak. We
thus interrogated our ATAC-seq data to determine the state of
chromatin accessibility at the 4538 patient-speciﬁc NANOG
peaks, and overall found no signiﬁcant changes in accessibility in
these regions between the patients and the control lines (Fig. 5c).
We note that nearly a quarter of the patient-speciﬁc NANOG
peaks were found in regions of repressed chromatin (Fig. 6c, e), in
line with recent studies which suggested that NANOG can bind
repressed chromatin like other pioneer pluripotency factors35,36.
Despite no changes in chromatin accessibility, the NANOG
ChIP-seq signal at the 4538 patient-speciﬁc NANOG peaks was
signiﬁcantly higher in the patient than in the control lines
(Wilcoxon’s rank-sum test p < 2.2 × 10−16 in all the patient vs
control pairwise comparisons; Fig. 6d, e). We hypothesized that
the increased NANOG binding detected in the patients’ cells
(Fig. 6d) could reﬂect increased NANOG expression (Fig. 6d). In
fact, several elegant studies in embryonic stem cells have
demonstrated that changes in NANOG dosage mark the
transition from an undifferentiated state (high NANOG), to a
state with differentiation potential (low NANOG)37–39. Importantly, it has been shown that SOX2 and OCT4 bind a cis-
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Fig. 6 Aberrant SOX2 and NANOG activity in the patient cells at CNCC day 5. a Spike-in normalized SOX2 ChIP-seq average proﬁle for 3284 patientspeciﬁc ATAC-seq peaks showing patient-speciﬁc SOX2 signal (spike-in normalized; CNCC Day 5). Statistical signiﬁcance was assessed with Wilcoxon’s
Rank-Sum test (p < 2.2 × 10−16 in all the patient vs control comparisons). b ATAC-seq heatmaps at the 3284 peaks shown in Fig. 5a reveal that these
regions display increased chromatin accessibility in the patients relative to the two control lines. c ATAC-seq heatmaps at 4538 patient-speciﬁc NANOG
peaks display no changes in accessibility between patient and control lines. d Spike-in normalized NANOG ChIP-seq heatmaps at 4538 patient-speciﬁc
NANOG peaks (spike-in normalized; CNCC Day 5). e Example of patient-speciﬁc NANOG peak in a region with no chromatin accessibility (CNCC Day 5). f
At CNCC Day 5, a cis-regulatory element in the promoter region of NANOG is more accessible in the patients than in the control lines. The same element
also displays higher SOX2 binding in the patients than in the controls. g Knockdown of ARID1B from Control Line-1 also elicits an increase in chromatin
accessibility at the cis-regulatory element in the promoter region of NANOG (CNCC Day 5).
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regulatory element in the promoter region of NANOG, likely
modulating its expression40,41. Thus, we examined this cisregulatory element in detail. As expected, at day 5 of iPSC-toCNCC differentiation, the chromatin accessibility at the
promoter-proximal element is signiﬁcantly higher in the two
patient lines than in the two controls (Student’s t test p = 0.0065;
Fig. 6f). Accordingly, increased chromatin accessibility correlates
with increased SOX2 binding on the cis-regulatory element
(Fig. 6f), perhaps explaining the higher NANOG gene expression
reported in patient-derived lines at day 5. At last, our shRNA
experiments also conﬁrmed these ﬁndings, demonstrating that
the knockdown of ARID1B in the Control line-1 line correlates
with a sizeable increase in accessibility at the NANOG cisregulatory element (Fig. 6g), thus suggesting that ARID1B-BAF
directly modulates NANOG expression dosage at the onset of
differentiation.
In sum, the ARID1B-haploinsufﬁcient lines exhibit the
persistent activity of two key pluripotency factors (SOX2,
NANOG) in the early and late stages of CNCC formation. The
aberrant activity of SOX2 and NANOG likely leads to impaired
lineage commitment and inefﬁcient CNCC formation.
A switch from ARID1A-BAF to ARID1B-BAF is necessary for
exit from pluripotency. We next wanted to elucidate how the
BAF complex compensated for ARID1B haploinsufﬁciency. As
mentioned above, ARID1A and ARID1B represent the only two
subunits of the BAF harboring an ARID domain, which is
leveraged by the complex to interact with the chromatin22. A
third ARID subunit (ARID2) is exclusive to a different conﬁguration of the complex (pBAF). ARID2 mutations have been
shown to cause a neurodevelopmental disorder that does not fully
recapitulate the Cofﬁn-Siris syndrome phenotype, although there
is some overlap42. Compensatory mechanisms between ARID1A
and ARID1B were recently demonstrated in ovarian cancer43.
Thus, we hypothesized that ARID1B-haploinsufﬁcient patientderived cells may compensate for partial loss of ARID1B with
ARID1A. To test this, we ﬁrst assessed ARID1A protein levels in
ARID1B-wt cells during CNCC formation and found that
ARID1A expression was complementary to ARID1B (Fig. 7a). In
agreement with the speciﬁc composition of the esBAF, which
requires ARID1A5,6, human iPSCs expressed high levels of
ARID1A and relatively low ARID1B (Fig. 7a). On the other hand,
at the initiation of iPSC-to-CNCC differentiation (day 1) ARID1B
was upregulated while ARID1A was strongly repressed to levels
barely detectable (Fig. 7a). ARID1B remained the only active
ARID1 subunit between days 1–5 (i.e., during the formation of
the neuroectodermal cells; Fig. 7a). Finally, on day 7, ARID1B was
abruptly downregulated and ARID1A was restored at high levels
on day 9. This latter switch corresponded to the beginning of the
differentiation of the neuroectodermal spheres into migratory
CNCCs (Fig. 7a). Together, these data suggested that throughout
the course of CNCC differentiation, multiple switches between
ARID1A and ARID1B occur and that these two ARID1 subunits
regulate speciﬁc developmental stages during CNCC formation.
Next, we proﬁled ARID1A protein levels during iPSC-toCNCC differentiation in patient-derived lines. Time-course
immunoblotting revealed that the temporary decommissioning
of ARID1A during neuroectoderm speciﬁcation (~days 1–7)
failed to occur in both of the patient cell lines (Fig. 7b). In fact, in
the patient lines, ARID1A protein levels were maintained
throughout the course of iPSC differentiation (days 1–11)
(Fig. 7b).
In addition to perpetual expression, there was an approximately ﬁvefold increase in ARID1A expression in patient cell
lines, relative to controls at day 5 (Patient 19: 4.9-fold; Patient 26:
10

5.1-fold; Fig. 7c), a time point which exhibited robust ARID1B
expression in control cells. Together, these data suggested that the
patient cells compensated for the partial loss of ARID1B by
maintaining aberrantly high ARID1A levels throughout the
differentiation process.
A recent study conducted on liver cells demonstrated that
ARID1A- and ARID1B-containing BAF may have antagonistic
functions in the transcriptional regulation of speciﬁc genes, with
ARID1B acting prevalently as a repressor of enhancer elements,
as opposed to the ARID1A, which mostly functions as an
activator44. Hence, we hypothesized that the perpetual and robust
ARID1A protein levels detected in patient-derived cells during
iPSC-to-CNCC differentiation, and speciﬁcally during neuroectoderm speciﬁcation, may result in the prolonged activity of
pluripotency enhancers. Consistent with the recent studies which
reported that the (ARID1A-containing) esBAF regulates pluripotency genes in iPSCs and ESCs4–6, ARID1A ChIP-seq
performed at the iPSC stage revealed that the 5540 pluripotency
enhancers and promoters were bound by ARID1A in all the four
lines (Fig. 7d; number of ARID1A peaks in iPSC ranged from
11,634 to 26,434 depending on the replicates). Conversely, the
same experiment conducted on day 5 of differentiation revealed
that while ARID1A binding was lost at the 5540 pluripotency
elements in control cell lines, it was maintained in patient cell
lines (Fig. 7d; the number of ARID1A peaks at day 5 in the
patient lines ranged from 2405 in P19 to 17,080 in P26, indicating
a potentially more widespread ARID1A activity in the patient line
showing the strongest molecular impairment). In summary, these
data indicated that the status of a set of ~5500 pluripotency
enhancers and promoters were regulated by ARID1A at the iPSC
stage and by ARID1B during exit from pluripotency and
neuroectodermal lineage commitment. Importantly, ARID1B
haploinsufﬁciency in patient cell lines triggered a compensatory
mechanism that resulted in persistent binding of ARID1A at
pluripotency enhancers throughout differentiation.
The ARID1B-BAF complex exclusively incorporates
SMARCA4 as an ATPase subunit. Finally, we addressed the
composition of the ARID1B-BAF complex at day 5 of iPSC-toCNCC differentiation. To do so, we performed immunoprecipitation of endogenous ARID1B followed by mass-spectrometry
(IP-MS). In control cells, ARID1B co-eluted with a total of 10
additional BAF subunits (hereafter ARID1B-BAF; Supplementary
Fig. 5a). In mammals, BAF complexes incorporate two widely
interchangeable and mutually exclusive ATPase subunits,
SMARCA2, and SMARCA4. Remarkably, SMARCA4 was the
only ATPase subunit identiﬁed as coeluting with ARID1B in our
IP-MS, while zero peptides of SMARCA2 were detected (Supplementary Fig. 5a). This suggests that ARID1B-BAF selectively
incorporates only SMARCA4 as a catalytic subunit during
CNCCs formation.
We repeated this experiment in the patient lines to determine if
perpetually active ARID1A replaced ARID1B in the ARID1B-BAF
or if instead, it was part of a completely different BAF conﬁguration.
We thus performed ARID1A IP-MS at day 5 in patient lines.
Notably, in the two patient lines ARID1A co-eluted with all the
other subunits of the ARID1B-BAF (Supplementary Fig. 5b). In
summary, the perpetual presence of ARID1A-BAF in patient cells
correlated with a very speciﬁc (and previously uncharacterized)
conﬁguration of the BAF complex (ARID1B-BAF), which was active
during exit from pluripotency and neuroectoderm speciﬁcation.
Intriguingly, the transcription factor SALL4 also co-eluted with
ARID1B at day 5, suggesting a possible interaction with the
complex. Like ARID1B, SALL4 is also dispensable for the
maintenance of the pluripotency networks, whereas it is essential

NATURE COMMUNICATIONS | (2021)12:6469 | https://doi.org/10.1038/s41467-021-26810-x | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26810-x

ARTICLE

Fig. 7 A switch between ARID1A-BAF and ARID1B-BAF is required for a successful exit from pluripotency. a Time-course immunoblot conducted using
Control Line-1 during CNCC differentiation shows that ARID1A is active at the iPSC stage, and abruptly downregulated at day 1 of differentiation. ARID1A
protein level is upregulated again after day 7, mirroring ARID1B’s downregulation at the same time point. Experiment repeated twice (different biological
replicates). Marker bars display kDa. b ARID1A time-course immunoblot in the two patient lines. Experiment repeated twice (different biological
replicates). Marker bars display kDa. c ARID1A immunoblot: both patient lines display aberrantly high ARID1A’s protein level at CNCC Day 5. Experiment
repeated twice (different biological replicates). Marker bars display kDa. d ChIP-seq for ARID1A in the two control lines and the two patient lines at iPSC
stage (day 0) and at CNCC Day 5. Spike-in normalized heatmaps are centered on the 5540 pluripotency enhancers. The UCSC screenshot shows ARID1A
and ARID1B binding at a patient-speciﬁc ATAC-seq peak (chr19:18,050,000–18,100,000) in the control and patient lines at iPSC stage and at CNCC Day 5.

for lineage commitment in early mammalian development, during
which it targets sites with binding motifs also recognized by SOX2,
OCT4, and NANOG45–48. SALL4 was previously shown to interact
with the NuRD repressive complex46, while interactions with BAF
have been largely unexplored. It was recently demonstrated that this
transcription factor has an afﬁnity for AT-rich regions49, thus
providing further support to the ARID1B-SALL4 interaction.
SALL4 mutations are also associated with developmental syndromes, including Okihiro syndrome, Holt-Oram syndrome, and
Townes-Brocks Syndrome50. Notably, the SALL4 gene is downregulated in the Cofﬁn-Siris patients at CNCC day 5 but not in
undifferentiated iPSCs, suggesting a possible feedback mechanism
between ARID1B and SALL4 during lineage commitment. Future
studies will be necessary to support the speculation that
SALL4 serves as an intermediator for ARID1B-BAF recruitment
at the pluripotency enhancers.

Discussion
ARID1B is a member of the evolutionarily conserved SWI/SNF
(BAF) chromatin remodeler22,51. De novo haploinsufﬁcient
mutations in the ARID1B gene cause severe neurodevelopmental
disorders, which affect both physical and cognitive development.
In this study, we investigated the role of Cofﬁn-Siris-associated
ARID1B mutations in the context of craniofacial development
and report the discovery of an unappreciated function of the BAF
complex: attenuation of the gene expression program associated
with pluripotency maintenance upon differentiation cues. We
found that this repressive function is performed at pluripotency
enhancers and promoters by a speciﬁc BAF complex conﬁguration (ARID1B-BAF), which is composed of nine subunits, with
the enzymatic activity seemingly carried out exclusively by
SMARCA4. It is worth noting that future studies will be necessary
to determine with enhancer repression is directly performed by
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ARID1B, or if ARID1B’s role is rather to prevent ARID1A from
binding at these enhancers to keep them active
As a consequence of the ARID1B mutations, Cofﬁn-Siris
patient cells fail to repress the pluripotency elements. This subsequently elicits aberrant SOX2 activity genome-wide, which in
turn leads to the upregulation of multiple pluripotency genes,
including NANOG and its associated gene network, and to the
downregulation of the genes responsible for coordinating the exit
from pluripotency (PPARα/RXRα pathway). We demonstrated
that these pluripotency enhancers are normally maintained in an
active state by ARID1A-BAF at the iPSC stage, and subsequently
repressed by the ARID1B-BAF throughout neuroectoderm formation, which is the ﬁrst stage of CNCC development.
A switch between ARID1A-BAF and ARID1B-BAF upon differentiation cues is hence necessary for commitment towards the
neuroectodermal lineage. We additionally report that a second
switch from ARID1B-BAF to ARID1A-BAF takes place later, when
the neuroectodermal spheres differentiate into CNCCs. This suggests
that ARID1B is likely the dominant ARID1 subunit during neuroectoderm speciﬁcation, whereas ARID1A regulates the following
stage, during which the neuroectodermal spheres differentiate into
migratory CNCCs. It is worth noting that the neuroectoderm not
only gives rise to all regions of the brain and central nervous system
(hindbrain, midbrain, forebrain, spinal cord, and motor neurons),
but also gives rise to the neural crest cells, which emanate out from
the dorsal aspect of the neural tube. Therefore, we speculate that the
dysregulation of neuroectoderm speciﬁcation caused by ARID1B
mutations may underlie both the cognitive impairment and craniofacial abnormalities that are typical of Cofﬁn-Siris syndrome.
This model is further supported by a signiﬁcant overlap of differentially expressed genes identiﬁed in our study (neural crest formation) and in a recently published ARID1B-KO-mouse model
(brain tissue)30.
Other studies have previously suggested that switches between
SWI/SNF subunits play important roles in cell fate determination.
For example, a switch between the two catalytic subunits
SMARCA4 and SMARCA2 mediates the activation of human
IFNγ-activated genes52. Similarly, a gain of the subunit BAF53a
in the neuron-speciﬁc BAF (nBAF) is required to control cell
cycle exit in developing neurons2,3. With our study, we discovered a binary switch between BAF subunits (ARID1A/
ARID1B), critical for the exit from pluripotency. Importantly, a
balance between pro-self-renewal and pro-differentiation signals
is pivotal for the determination of stem cell fate53. We demonstrate that such balance is lost in Cofﬁn-Siris patients, whose cells
are unable to perform the ARID1A/ARID1B switch at the pluripotency enhancers at the onset of differentiation. This switch is
essential to successfully complete CNCC differentiation.
Pluripotency is orchestrated by a transcription factor network
that needs to be extinguished in an orderly manner to enable
lineage commitment and differentiation53–55. We ﬁnd that
ARID1B-BAF plays an essential role in this process, by means of
repressive activity at pluripotency enhancers for the SOX2,
NANOG, and OCT4 networks. Similarly, an association between
SOX3 and the SMARCA2 ATPase subunit of BAF was recently
suggested in a study of neural development in the NicolaidesBaraitser syndrome56. It is worth noting that Cofﬁn-Siris and
Nicolaides-Baraitser syndromes share many physical and neurological phenotypes56–58.
The BAF complex is predominantly considered as a transcriptional activator, which balances the polycomb repressor complexes
(PRC1, PRC2) in the modulation of gene expression7,59. Despite this
widely held belief, repressive activity for BAF has been reported. For
instance, a study conducted on hepatocellular carcinoma cell lines
uncovered that ARID1A-containing BAF activates and represses
roughly equal numbers of genes, while ARID1B-containing BAF was
12

found to primarily repress enhancer activity44. Our experiments
corroborate these ﬁndings, supporting an enhancer-repressor function for ARID1B-BAF. We demonstrate that the repressive activity
of ARID1B-BAF is speciﬁc to a set of ~4900 enhancers and ~600
promoters, enriched for SOX2- and NANOG-binding sites. In
control cells, these cis-regulatory elements are highly active at the
iPSC stage, moderately active in the ﬁrst four days of differentiation,
and ﬁnally repressed by day 5, a time point at which we observed the
peak of ARID1B protein expression. Cofﬁn-Siris patient-derived
iPSC lines exhibit aberrant chromatin accessibility at these cisregulatory elements for many days after the onset of iPSC-to-CNCC
differentiation, enforcing a perpetual pluripotency signature which
persists even after 2 weeks of differentiation.
Patient 26-derived cells display the most extreme cellular and
molecular phenotype, with a large population of cells remaining
pluripotent at day 14 of differentiation, likely as a consequence of
higher SOX2, OCT4, and NANOG expression and activity. Cells
derived from this patient also show the highest levels of ARID1A
binding at these enhancers at day 5 of CNCC differentiation.
Although it is difﬁcult to formally compare disease severity since
there are no accepted severity scales for Cofﬁn-Siris syndrome, it
is worth noting that Patient 26 had a more severe disease process
than Patient 19. For example, Patient 26 was not able to speak at
7 years, whilst Patient 19 started speaking at 4 years. In addition,
Patient 26 was affected by pyloric stenosis, a congenital anomaly
in the digestive tract thought to be associated with impaired
migration of the enteric neural crest. We consider it unlikely that
the difference is caused solely by the mutations in ARID1B, since
both patients show a comparable reduction in ARID1B protein
levels. We speculate that additional genetic factors may cooperate
with ARID1B haploinsufﬁciency to determine the clinical severity
of the syndrome. Even if our study is based on only two patients
vs two control lines, multiple assays (ATAC-seq, ChIP-seq, RNAseq, and differentiation assays) highlighted important differences
during the differentiation of wild-type vs ARID1B-mutant iPSCs
to CNCCs. However, additional experiments with a larger set of
patient-derived cell lines would be required to support this model.
Furthermore, it would also be important to investigate other
differentiation lineages to elucidate whether the ARID1A/ARID1B
switch is only important for neural crest differentiation or if, instead,
it represents a more widespread mechanism utilized by stem cells to
exit the pluripotent state and undergo lineage commitment.
Finally, further investigations will be necessary to elucidate the
mechanism(s) responsible for the repressive activity of ARID1BBAF. Recent studies have demonstrated that the function of BAF
(including ARID1A-BAF) as a transcriptional activator is mediated by the AP-1 transcription factors56,60,61. On the other hand,
little is known of potential co-factors mediating the repressive
function of ARID1B-BAF.
Methods
Antibodies. ARID1B ChIP-Seq: Abcam ab57461. ARID1B western blot: SantaCruz sc-32762 and Abcam ab57461. ARID1A ChIP-Seq: GeneTex GTX129433.
ARID1A western blot: Cell Signaling Technologies 12354 S. Beta-Actin western
blot: Cell Signaling Technologies 8457 P. SOX2 ChIP-Seq: Active Motif 39843.
NANOG ChIP-Seq: R&D Systems AF1997. H3K27ac ChIP-Seq: Abcam ab4729.
GAPDH western blot: Cell Signaling Technologies 5174 T. CD10 Flow Cytometry:
Miltenyi Biotech 130-124-262. CD99 Flow Cytometry: Miltenyi Biotech 130-121086. SSEA4 Flow Cytometry: Biolegend 330417. TRA-1-60-R Flow Cytometry:
Biolegend 330609. IgG ChIP-qPCR: Cell Signaling Technologies 2729 S. Cell Signaling HRP-conjugated anti-rabbit (7074 S) and anti-mouse (7076 S) were used as
secondary antibodies in western blot. Spike-in Antibody: Active Motif 61686.
Spike-in Chromatin: Active Motif 53083. Antibodies used in immunoﬂuorescence:
Anti-Mouse OCT4 (STEMCELL TECHNOLOGIES, 60059, 1:200); Rabbit Monoclonal Anti-Sox9 (abcam, ab185230,1:250); pPolyclonal Goat Anti-Nanog (R&D
System, AF1997-SP,1:20); donkey anti-goat IgG (H + L) Alexa 488 (Jackson
ImmunoResearch, 705-545-003, 1:500); donkey anti-mouse IgG (H + L) Alexa 647
(Jackson ImmunoResearch, 715-605-150, 1:500); Donkey anti-rabbit IgG (H + L)
Cy3 (Jackson ImmunoResearch, 11-165-152, 1:500)., Monoclonal mouse anti-
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human TRA-1-60 Antibody (Millipore MAB4360C3,1:100), Monoclonal mouse
Anti-Stage-Speciﬁc Embryonic Antigen-4 Antibody (Millipore, MAB4304,1:100),
Polyclonal Goat Anti- Human/Mouse Oct-3/4 Antibody (R&D System,
AF1759,1:20).
Human iPSC culture. Control iPSC lines were obtained from the iPSC Core of the
University of Pennsylvania (Control line-1: SV20 line, male, age 43) and from the
Coriell Institute for Medical Research (Camden, NJ. Control line-2: GM23716,
female, age 16). Skin ﬁbroblasts from the two pediatric Cofﬁn-Siris patients (one
teenager one young adult) were obtained by the team of Dr. Gijs Santen at Leiden
University. Patient 19 is a female, while Patient 26 is a male.
For the usage of the patient samples, we complied with all relevant ethical
regulations for work with human participants, and that informed consent was
obtained by Leiden University (LUMC), which approved the protocol under the
coordination of Dr. Gijs Santen. The study was conducted in accordance with the
criteria set by the Declaration of Helsinki. The protocol to make iPSCs was
approved by the IRB at LUMC. Collecting patient material and establishing iPSCs
have all been performed according to local (LUMC) IRB protocols.
The ﬁbroblasts were reprogrammed into iPSCs with the polycistronic lentiviral
vector LV.RRL.PPT.SF.hOKSM.idTomato.-preFRT by LUMC human iPSC Hotel
as described elsewhere62,63.
Multiple clones per line were derived. For each clone, pluripotency was assessed
by immunoﬂuorescence microscopy using antibodies against NANOG, OCT3/4,
SSEA4, and Tra-1-81 under maintenance conditions and antibodies against
(TUBB3, AFP, and CD31) after spontaneous differentiation into the three germ
layers as described elsewhere62. Clones with proper pluripotent characteristics were
selected for downstream usage. Karyotyping by G binding was assessed for all the
four lines by the Leiden University Medical Center and short tandem repeat (STR)
proﬁling was performed by the Leiden University Medical Center and then
replicated by the Stem Cell and Regenerative Neuroscience Center at Thomas
Jefferson University. The iPSC lines were expanded in feeder-free, serum-free
mTeSR™1 medium (STEMCELL Technologies). Cells were passaged ~1:10 at 80%
conﬂuency using ReLeSR (STEMCELL Technologies) and small cell clusters
(50–200 cells) were subsequently plated on tissue culture dishes coated overnight
with Geltrex™ LDEV-Free hESC-qualiﬁed Reduced Growth Factor Basement
Membrane Matrix (Fisher-Scientiﬁc).
CNCC differentiation. The iPSC lines were differentiated into CNCC as previously
described24. In brief, iPSCs were treated with CNCC Derivation media: 1:1 Neurobasal medium/D-MEM F-12 medium (Invitrogen), 0.5× B-27 supplement with
Vitamin A (50× stock, Invitrogen), 0.5× N-2 supplement (100× stock, Invitrogen),
20 ng/ml bFGF (Biolegend), 20 ng/ml EGF (Sigma-Aldrich), 5 µg/ml bovine insulin
(Sigma-Aldrich) and 1× Glutamax-I supplement (100× stock, Invitrogen). Medium
(3 ml) was changed every day. Three days after the appearance of the migratory
CNCC, cells were detached using accutase and placed into geltrex-coated plates.
The early migratory CNCCs were then transitioned to CNCC early maintenance
media: 1:1 Neurobasal medium/D-MEM F-12 medium (Invitrogen), 0.5× B-27
supplement with Vitamin A (50× stock, Invitrogen), 0.5× N-2 supplement (100×
stock, Invitrogen), 20 ng/ml bFGF (Biolegend), 20 ng/ml EGF (Sigma-Aldrich),
1 mg/ml bovine serum albumin, serum replacement grade (Gemini Bio-Products #
700-104 P) and 1× Glutamax-I supplement (100× stock, Invitrogen).
ARID1B Knockdown. To make concentrated lentivirus, HEK293T cells were
transfected with a pLenti plasmid in which we cloned an shRNA for ARID1B (GPP
Web Portal: TRCN0000107361). iPSCs were lentivirally transduced by incubating
the cells with concentrated virus overnight at 37° C. The next morning the media
was changed, and 2 mg/ml puromycin (InvivoGen) were added 24 h after infection.
After 72 h, the iPSCs that survived the selection were then differentiated in CNCC
using the above-described protocol, and collected at Day 5 for the genomic
experiments. The cells were kept under puromycin selection for the entire duration
of the differentiation. The knock-down efﬁciency was quantiﬁed via western blot.
Flow cytometry analysis of surface markers. To obtain a single-cell suspension
for ﬂow cytometry analysis, control and patient cells were treated with Accutase for
5 min. Cells were then washed with cold phosphate-buffered saline (PBS)-2% fetal
bovine serum (FBS) and live cells were counted. 1 × 106 cells/condition were
resuspended in 100 μL PBS-2% FBS and stained. For pluripotency evaluation, 4 µl
of the respective antibodies were used: APC anti-human SSEA4 antibody (Biolegend, #330417) and PE anti-human TRA-1-60-R antibody (Biolegend, #330609).
For analysis of differentiation, 2 µl of the respective antibodies were used: FITC
anti-human CD10 (Miltenyi Biotec, #130-124-262) and APC anti-human CD99
(Miltenyi Biotec, #130-121-096). Cells were incubated for 15 min on ice and
protected from light, before transferring them into FACS tubes containing an
additional 300 μL PBS-2% FBS. Flow cytometry data were acquired using a BD LSR
II ﬂow cytometer and analyzed with FlowJo Software version 10.7.
Western blot. For total lysate, cells were harvested and washed three times in 1×
PBS and lysed in radioimmunoprecipitation assay buffer (RIPA buffer) (50 mM
Tris-HCl pH7.5, 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS,
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500 μM DTT) with proteases inhibitors. Twenty μg of whole cell lysate were loaded
in Novex WedgeWell 4–20% Tris-Glycine Gel (Invitrogen) and separated through
gel electrophoresis (SDS–PAGE) Tris-Glycine-SDS buffer (Invitrogen). The proteins were then transferred to ImmunBlot PVDF membranes (ThermoFisher) for
antibody probing. Membranes were incubated with 10% BSA in TBST for 30 min
at room temperature (RT), then incubated for variable times with the suitable
antibodies diluted in 5% BSA in 1× TBST, washed with TBST, and incubated with a
dilution of 1:10000 of secondary antibody for one hour at RT. The antibody was
then visualized using Super Signal West Dura Extended Duration Substrat
(ThermoFisher) and imaged with Amersham Imager 680. Full membranes
(uncropped) of the blots presented in the main ﬁgures are available as source
data ﬁle.
Cell fractionation. In all, 5 × 106 cells/condition were collected and suspended in
E1 buffer (50 mM HEPES-KOH, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5%
NP-40, 0.25% Triton X-100, 1 mM DTT, 1× Proteinase Inhibitor) followed by a
centrifugation step of 1100 × g at 4 °C for 2 min. The cytoplasmic fraction was
collected in a fresh tube. Cells were washed two more times with E1 buffer. Pellet
was subsequently suspended in E2 buffer (10 mM Tris-HCl, 200 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 1× Proteinase Inhibitor) followed by a centrifugation step
of 1100 × g at 4 °C for 2 min. The nuclear fraction was collected in a fresh tube.
Cells were washed two more times with E2 buffer. After the third wash, the pellet
was suspended in E3 buffer (500 mM Tris-HCl, 500 mM NaCl, 1× Proteinase
Inhibitor) and sonicated for 15 sec (5 sec ON/ 5 sec OFF). Cytoplasmic, nuclear,
and chromatin fractions were centrifuged at 16,000 × g for 10 min at 4 °C.
Immunoﬂuorescence. Upon ﬁxation (4% PFA for 10 min), cells were permeabilized in blocking solution (0.1% Triton X-100, re PBS, 5% normal donkey serum)
and then incubated with the antibody of interest. The total number of cells in each
ﬁeld was determined by counterstaining cell nuclei with 4,6-diamidine-2-phenylindole dihydrochloride (Sigma-Aldrich; 50 mg/ml in PBS for 15 min at RT).
Immunostained cells were mounted in Aqua-Poly/Mount (Polysciences) and
analyzed at epi-ﬂuorescent or confocal microscopy, using a Nikon A1R+. Images
were captured with a ×40 objectives and a pinhole of 1.2 Airy unit. Analyses were
performed in sequential scanning mode to rule out cross-breeding between
channels.
Real-time quantitative polymerase chain reaction (RT-qPCR). Cells were lysed
in Tri-reagent and RNA was extracted using the Direct-zol RNA MiniPrep kit
(Zymo Research). In all, 600 ng of template RNA was retrotranscribed into cDNA
using RevertAid ﬁrst-strand cDNA synthesis kit (Thermo Scientiﬁc) according to
manufacturer directions. 15 ng of cDNA were used for each real-time quantitative
PCR reaction with 0.1 μM of each primer, 10 μL of PowerUp™ SYBR™ Green Master
Mix (Applied Biosystems) in a ﬁnal volume of 20 μl, using QuantStudio 3 RealTime PCR System (Applied Biosystem). Thermal cycling parameters were set as
follows: 3 min at 95 °C, followed by 40 cycles of 10 s at 95 °C, 20 s at 63 °C followed
by 30 s at 72 °C. Each sample was run in triplicate. 18 S rRNA was used as normalizer. Primer sequences are reported in Supplementary Data 7.
ChIP-Seq and ChiP-qPCR. Samples from different conditions were processed
together to prevent batch effects.
For SOX2, NANOG, and H3K27ac, for each replicate, 10 million cells were
cross-linked with 1% formaldehyde for 5 min at RT, quenched with 125 mM
glycine, harvested, and washed twice with 1× PBS. The pellet was resuspended in
ChIP lysis buffer (150 mM NaCl, 1% Triton X-100, 0,7% SDS, 500 μM DTT,
10 mM Tris-HCl, 5 mM EDTA) and chromatin was sheared to an average length of
200–500 bp, using a Covaris S220 Ultrasonicator. The chromatin lysate was diluted
with SDS-free ChIP lysis buffer. For ChIP-seq, 10 µg of antibody (3 µg for
H3K27ac) was added to 5 µg of sonicated chromatin along with Dynabeads Protein
A magnetic beads (Invitrogen) and incubated at 4 °C overnight. For SOX2 and
NANOG ChIP-seq, 10 ng of spike-in Drosophila chromatin (Active Motif) was
added to each sample with 2 µg spike-in antibody (Active Motif). On day 2, beads
were washed twice with each of the following buffers: Mixed Micelle Buffer
(150 mM NaCl, 1% Triton X-100, 0.2% SDS, 20 mM Tris-HCl, 5 mM EDTA, 65%
sucrose), Buffer 500 (500 mM NaCl, 1% Triton X-100, 0.1% Na deoxycholate,
25 mM HEPES, 10 mM Tris-HCl, 1 mM EDTA), LiCl/detergent wash (250 mM
LiCl, 0.5% Na deoxycholate, 0.5% NP-40, 10 mM Tris-HCl, 1 mM EDTA) and a
ﬁnal wash was performed with 1× TE. Finally, beads were resuspended in 1× TE
containing 1% SDS and incubated at 65 °C for 10 min to elute immunocomplexes.
Elution was repeated twice, and the samples were further incubated overnight at
65 °C to reverse cross-linking, along with the untreated input (5% of the starting
material). On day 3, after treatment with 0.5 mg/ml Proteinase K for 1 h at 65 °C,
DNA was puriﬁed with Zymo ChIP DNA Clear Concentrator kit and quantiﬁed
with QUBIT.
For ARID1A and ARID1B ChIP-Seq, 10 million cells were cross-linked with
EGS (150 mM) for 30 min at RT followed by a second cross-link with 1%
formaldehyde for 15 min at RT. The formaldehyde was quenched by adding glycine
(0.125 M) for 10 min at RT. Cells were washed twice with 1× PBS. Pellet was
resuspended in buffer LB1 (50 mM Hepes-KOH, 140 mM NaCl, 1 mM EDTA, 10%
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Glycerol, 0.5% NP-40, 0.255 Triton X-100), incubated 10 min at 4 °C followed by a
centrifugation step of 600 g for 5 min at 4 °C. Pellet was suspended in buffer LB2
(10 mM Tris-HCl, 20 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) incubated 10 min at
4 °C followed by a centrifugation step of 600 g for 5 min at 4 °C. Cells were then
resuspended in buffer LB3 (10 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 0.1% Na-DOC, 0.5% N-laurosylsarcosine) incubated 10 min at 4 °C
followed by a centrifugation step of 600 g for 5 min at 4 °C. Pellet was suspended in
LB3 and chromatin was sheared to an average length of 200–500 bp, using a
Covaris S220 Ultrasonicator. For each sample, 15μg of sonicated chromatin was
incubated at 4 °C overnight along with Dynabeads Protein G conjugated with 10μg
of antibody. On day 2, beads were washed once with each of the following buffers:
WB1 (50 mM Tris-HCl, 150 mM NaCl, 0.15 SDS, 0.1% Na-DOC, 1% Triton X-100,
1 mM EDTA), WB2 (50 mM Tris-HCl, 500 mM NaCl, 0.15 SDS, 0.1% Na-DOC,
1% Triton X-100, 1 mM EDTA), WB3 (10 mM Tris-HCl, 250 mM LiCL, 0.55 NP40. 0.55 Na-DOC, 1 mM EDTA), TE Buffer (10 mM Tris-HCl, 1 mM EDTA).
Finally, beads were resuspended in EB (10 mM tris-HCl, 0.55 SDS, 300 mM NaCl,
5 mM EDTA) and incubated at 65 °C for 30 min to elute immunocomplexes.
Elution was repeated twice, and the samples were further incubated overnight at
65 °C to reverse cross-linking, along with the untreated input (5% of the starting
material). On day 3, after treatment with 0.5 mg/ml Proteinase K for 1 h at 65 °C.
For all ChIP-seq experiments, barcoded libraries were made with NEB ULTRA
II DNA Library Prep Kit for Illumina, and sequenced on Illumina NextSeq 500,
producing 75 bp SE reads.
For ChIP-qPCR, on day 1 the sonicated lysate was aliquot into single
immunoprecipitations of 2.5 × 106 cells each. A speciﬁc antibody or a total rabbit
IgG control was added to the lysate along with Protein A magnetic beads
(Invitrogen) and incubated at 4 °C overnight. On day3, ChIP eluates and input
were assayed by real-time quantitative PCR in a 20 μl reaction with the following:
0.4 μM of each primer, 10 μl of PowerUp SYBR Green (Applied Biosystems), and
5 μl of template DNA (corresponding to 1/40 of the elution material) using the fast
program on QuantStudio qPCR machine (Applied Biosystems). Thermal cycling
parameters were: 20 sec at 95 °C, followed by 40 cycles of 1 sec at 95 °C, 20 sec
at 60 °C.
ChIP-seq analyses. After removing the adapters, the sequences were aligned to the
reference hg19, using Burrows-Wheeler Alignment tool, with the MEM
algorithm64. Aligned reads were ﬁltered based on mapping quality (MAPQ > 10) to
restrict our analysis to higher quality and likely uniquely mapped reads, and PCR
duplicates were removed. We called peaks for each individual using MACS265
(H3K27ac) or Homer66, at 5% FDR, with default parameters.
RNA-seq. Cells were lysed in Tri-reagent (Zymo research) and total RNA was
extracted using Quick-RNA Miniprep kit (Zymo research) according to the
manufacturer’s instructions. RNA was further quantiﬁed using DeNovix DS-11
Spectrophotometer while the RNA integrity was checked on Bioanalyzer 2100
(Agilent). Only samples with RIN value above 8.0 were used for transcriptome
analysis. RNA libraries were prepared using 1 μg of total RNA input using NEBNext® Poly(A) mRNA Magnetic Isolation Module, NEBNext® UltraTM II Directional RNA Library Prep Kit for Illumina® and NEBNext® UltraTM II DNA
Library Prep Kit for Illumina® according to the manufacturer’s instructions (New
England Biolabs).

13,000 × g for 30 min, and the supernatant was kept as a nuclear extract. The
nuclear extract was dialyzed overnight in BC80 (20 mM Tris pH 8.0, 80 mM KCl,
0.2 mM EDTA, 10% glycerol, 1 mM B-mercaptoethanol, 0.2 mM phenylmethylsulfonyl ﬂuoride), cleared, and stored at −80 °C. For the IP, 1.5 mg of
nuclear extract was incubated for 3 h at 4 °C with 6 μg ARID1B antibody and 50 μL
of Dynabeads Protein A, and the control IP was performed with 0.75 mg of nuclear
extract and 25 μL of Dynabeads Protein A. Beads were washed three times with coIP buffer, followed by a ﬁnal wash with 0.05% NP-40 in PBS. Elution was performed by agitation in 0.1 M glycine pH 3.0 for one minute, and 1 M Tris base pH
11.0 was added to neutralize the pH of the eluate. Eluates were prepared for
SDS–PAGE and run on a Novex WedgeWell 10% Tris-Glycine Gel (Invitrogen)
with Tris-Glycine-SDS buffer (Bio-Rad), at 110 V for 10 min. The gel was stained
with Colloidal Blue staining kit (Invitrogen), and further processed at the proteomics facility at the Wistar Institute. In brief, the gel lanes were excised, reduced
with TCEP, alkylated with iodoacetamide, and digested with trypsin. Tryptic
digests were analyzed using LC-MS/MS (a standard 90 min LC gradient on the
Thermo Q Exactive HF mass spectrometer). MS/MS spectra were searched with
full tryptic speciﬁcity against the UniProt human database (10/02/2020) using
MaxQuant 1.6.17.0, and also searched for the common protein N-terminal acetylation, Asn deamidation, and Met oxidation. The protein and peptide false discovery rate was set at 1%.
Statistical and genomic analyses. All statistical analyses were performed using R
v3.3.1. BEDtools v2.27.172 was used for genomic analyses. Pathway analysis was
performed with Ingenuity-Pathway Analysis Suite (QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). Motif analyses were performed using the Meme-Suite73, and speciﬁcally with the MemeChIP application. Fasta ﬁles of the regions of interest were produced using BEDTools v2.27.1. Shufﬂed input sequences were used as background. E values <0.001
were used as a threshold for signiﬁcance73.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The data that support this study are available from the corresponding author upon
reasonable request. The original genome-wide data generated in this study have been
deposited in the GEO database under accession code GSE169654. The proteomic data
generated in this study have been deposited in ProteomeXchange Consortium via the
PRIDE partner repository under the accession code PXD028557. Source data are
provided with this paper.
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